Cosmos Health Expects Record Revenue Driven by Fast Growth in Online Subscriptions

2026-10-21 companies

Chicago, Tuesday, 20 October 2026.
Cosmos Health reaffirmed its 2026 outlook exceeding $90 million in revenue, powered by strong pharmaceutical manufacturing and a 42% surge in U.S. online subscriptions over just five days.

Cosmos Health Reaffirms 2026 Revenue Outlook

Cosmos Health Inc. (NASDAQ:COSM) has reaffirmed its full-year 2026 revenue outlook exceeding $90 million following record preliminary nine-month results [1]. CEO Greg Siokas announced the figures in a shareholder letter issued on October 20, 2026, highlighting a 19% year-over-year increase to $54.3 million [1]. The company expects the fourth quarter of 2026 to generate approximately $35.7 million in revenue, marking a significant increase from the previous year [1]. This guidance suggests the largest single-year revenue increase in the company’s history, driven by diversified growth engines [1].

U.S. Subscription Surge

A primary driver of this growth is the rapid expansion of the company’s U.S. e-commerce subscription model [2]. As of October 19, 2026, active U.S. subscriptions reached 8,940, representing a 42.198 increase from the 6,287 reported just five days prior on October 14, 2026 [2]. The company projects subscription revenue will contribute approximately $11.5 million to the fourth quarter U.S. outlook [4]. Monthly subscription value at standard renewal pricing hit $1,325,338 as of October 19, 2026, up 44% from the previous week [4].

Manufacturing and Distribution Drivers

Beyond direct sales, pharmaceutical contract manufacturing at Cana Laboratories continues to scale, with the pipeline growing sixfold since mid-2024 [1]. Distribution volumes at CosmoFarm have also risen, serving more than 1,500 pharmacies with revenue up approximately 4.3 times under Cosmos Health ownership [1]. These operational expansions support the company’s target to expand gross margins to 35.5% by fiscal 2029 [1]. Previous results from May 21, 2026, showed Q1 2026 revenue of $17.9 million, setting a precedent for the current growth trajectory [3].

Market Performance and Future Reports

In secondary market trading, Cosmos Health stock closed at USD 0.33 on October 16, 2026, reflecting a market capitalization of approximately USD 33.3 million [7]. Investors are looking toward the next scheduled earnings report date on November 17, 2026, for further financial clarification [7]. The company expects U.S. daily sales to increase from $60,000 at the start of Q4 to over $200,000 by year-end 2026 [4]. Analysts note that sustained renewals and margin stability will be key factors for valuation moving forward [5].

Sources

Pharmaceutical Industry Cosmos Health